Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies
Conclusion:IADL impairment was associated with inferior PFS and OS, supporting previous studies (2, 3) identifying IADL as an important predictor for alloHCT. In univariate analysis, IADL was a stronger predictor of post-transplant outcomes than traditional prognostication tools such as age, HCT-CI, and provider-KPS. MOS Physical Health score was associated with multiple poor outcomes including NRM and LOS, suggesting a primary impact on alloHCT toxicity. Multivariate analyses, as well as examination of other CGA variables, are ongoing.References:J Clin Oncol. 2011 Apr 1;29(10):1290-6.Haematologica. 2014 Aug;99(8):1373-9.Bone Marrow Transplant. 2018 May;53(5):565-575.Figure.DisclosuresAndreadis: Genentech: Consultancy, Employment; Gilead: Consultancy; Juno: Research Funding; Novartis: Consultancy, Research Funding; Pharmacyclics: Consultancy; Seattle Genetics: Consultancy; Kite: Consultancy; Celgene: Consultancy; Bayer: Consultancy; Astellas: Consultancy. Logan: Napajen: Consultancy; Adaptive Biotech: Consultancy; Shire: Consultancy; Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Incyte: Consultancy; Jazz Pharmaceuticals: Consultancy, Research Funding; Amgen: Consultancy; Astellas: Research Funding; Pharmacyclics: Research Funding; Kite: Research Funding. Mannis: Agios: Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees; NKarta: Membership on an entity's Board of Directors or advisory committees. Smith: Astellas Pharma...
Source: Blood - Category: Hematology Authors: Huang, L.-W., Huang, C.-Y., Andreadis, C., Logan, A. C., Mannis, G. N., Smith, C. C., Gaensler, K. M., Martin, T. G., Damon, L. E., Steinman, M. A., Olin, R. L. Tags: 904. Outcomes Research-Malignant Conditions: Poster II Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Biotechnology | Bone Marrow Transplant | Cancer | Cancer & Oncology | Employment | Genetics | Geriatrics | Hematology | Hodgkin's Disease | Legislation | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Myeloproliferative Disorders | Non-Hodgkin's Lymphoma | Pfizer | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants